CHEK2 and breast cancer: After adjustment for potential confounders (Table 2), again, CHEK2 c.1100delC status was not significantly associated with differences in overall survival (HR = 0.69; 95 %CI = 0.43–1.08) and BC-specific survival (HR = 0.77; 95 %CI = 0.42–1.39).